Psychiatr. pro Praxi, 2007; 2: 77-80

Depression and pain comorbidity

MUDr. Prim. Michal Maršálek CSc
Psychiatrická léčebna Bohnice, Praha

The presence and intensity of a chronic painful physical condition influences strongly the frequency and severity of depressive symptoms in patients with major depression. The pain is found in nearly half of subject with major depressive disorder. Painful symptoms predict more severe form of depression, a longer time to remission, and may be a marker of resistency to treatment. The emotional and painful physical symptoms of depression are particularly regulated by serotonergic and noradrenergic pathways in the brain and spinal cord. Data from controlled clinical trials support the suggestion that medication with dual action appears to be the most robust in both antidepressive and analgetic efficacy.

Keywords: depression, pain, epidemiology, pathophysiology, dual antidepressants, venlafaxine, duloxetine

Published: April 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Maršálek M. Depression and pain comorbidity. Psychiatr. praxi. 2007;8(2):77-80.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Bair MJ, Robinson RL, Katon W, Kroenke K. Depression and pain comorbidity: a literature review. Arch Intern Med 2003; 163: 2433-2445. Go to original source... Go to PubMed...
    2. Bair MJ, Robinson RL, Eckert GJ, Stang PE, Croghan TW, Kroenke K. Impact of pain on depression treatment response in primary care. Psychosomat Med 2004; 66: 17-22. Go to original source... Go to PubMed...
    3. Češková E. Duálně působící antidepresiva. Čes Slov Psychiatrie 2005; 101: 207-212.
    4. Češková E. Duálně působící antidepresiva. Remedia 2006; 16: 594-597.
    5. Delgado PL. Common pathways of depression and pain. J Clin Psychiatry 2004; 65 (suppl 12): 16-19. Go to original source...
    6. Entsuah AR. Venlafaxine vs SSRIs: comparison of somatic symptom resolution. Word J Biol Psychiatry 2004; 5 (Suppl 1): 92-97.
    7. Fava M, Mallinckrodt CH, Detke MJ, Watkin JG, Wohlreich MM. The effect of duloxetine on painful physical symptoms in depressed patients: Do improvements in these symptoms result in higher remission rates? J Clin Psychiatry 2004; 65: 521-530. Go to original source... Go to PubMed...
    8. Goldstein DJ, Lu Y, Detke MJ, Hudson J, Iyengar S. Effects of duloxetine on painful physical symptoms associated with depression. Psychosomatics 2004; 46: 17-28. Go to original source... Go to PubMed...
    9. Greden JF. Physical symptoms of depression: unmet needs. J Clin Psychiatry 2003; 64 (suppl 7): 5-11.
    10. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62. Go to original source... Go to PubMed...
    11. Honzák R. Adjuvantní analgetická léčba. Remedia 1995; 5: 39-46.
    12. Höschl C. Bolest a deprese. Bolest 1999; 2: 113-115.
    13. Judd LL, Akiskal HS, Maser JD, Zeller PJ, Endicott J, Coryell W, Paulus MP, Kunovac JL, Leon AC, Mueller TI, Rice JA, Keller MB. Major depressive disorder: A prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Dis 1998; 50: 97-108. Go to original source... Go to PubMed...
    14. Karp JF, Scott J, Houck P, Reynolds III CF, Kupfer DJ, Frank E. Pain predicts longer time to remission during treatment of recurrent depression. J Clin Psychiatry 2005; 66: 591-597. Go to original source... Go to PubMed...
    15. Kellner R, Sheffield BF. The one-week prevalence of symptoms in neurotic patients and normals. Am J Psychiatry 1973; 130: 102-105. Go to original source... Go to PubMed...
    16. von Knorring L, Perris C, Eismann M, Eriksson U, Perris H. Pain as a symptom in depressive disorders, pt 2: relationship to personality traits as assessed by means of KSP. Pain 1983; 17: 377-384. Go to original source... Go to PubMed...
    17. Kršiak M. Antidepresiva a bolest. Bolest 1999; 2: 116-118.
    18. Lucki I. The spectrum of behaviors influenced by serotonin. Biol Psychiatry 1998; 44: 151-162. Go to original source... Go to PubMed...
    19. Mallinckrodt CH, Raskin J, Wohlreich MM, Watkin JG, Detke MJ. The efficacy of duloxetine. A comprehensive summary of results from MMRM and LOCF-ANCOVA in eight clinical trials. BMC Psychiatry 2004; 4: 1-9. Go to original source... Go to PubMed...
    20. Moldin SO, Scheftner WA, Rice JP, Nelson E, Knesevich MA, Akiskal H, Association between major depressive disorder and physical illness. Psychol Med 1993; 23: 755-761. Go to original source... Go to PubMed...
    21. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382-389. Go to original source... Go to PubMed...
    22. Murray CJL, Lopez AD (eds). The global burden of disease and injury series, vol 1: A comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Cambridge, Mass: Harvard Univerity Press; 1996.
    23. Ohayon MM, Schatzberg AF. Using chronic pain to predict depressive morbidity in the general population. Arch Gen Psychiatry 2003; 60: 39-47. Go to original source... Go to PubMed...
    24. Ohayon MM. Specific characteristics of the pain/depression association in the general population. J Clin Psychiatry 2004; 65 (suppl 12): 5-9.
    25. Paykel ES, Ramana R, Cooper Z, Hayhurst H, Kerr J, Barocka A. Residual symptoms after partial remission: an important outcome in depression. Psychol Med 1995; 25: 1171-1180. Go to original source... Go to PubMed...
    26. Rokyta R. Bolest a její patofyziologie. Psychiatrie 1998; 2: 103-107.
    27. Rokyta R. Psychogenní bolest. Psychiatrie 2004; 8: 21-25.
    28. Rokyta R. Patofyziologie bolesti s ohledem na klinické souvislosti. In: Rokyta R, Kršiak M., Kozák J. (eds). Bolest - monografie anelgeziologie. Praha, Tigis 2006: 76-86.
    29. Scott AJ, Monk TH, Brink LL. Shiftwork as a risk factor for depression: a pilot study. Int J Ocup Environ Health 1997; 3 (suppl 2): S2-S9.
    30. Silverstein B. Gender difference in the prevalence of clinical depression: the role played by depression association with somatic symptoms. Am J Psychiatry 1999; 156: 480-482. Go to original source... Go to PubMed...
    31. Silverstein B. Gender difference in the prevalence of somatic versus pure depression: a replication. Am J Psychiatry 2002; 159: 1051-1052. Go to original source... Go to PubMed...
    32. Simon GE, VonKorff M, Piccinelli M, Fullerton C, Ormel J. An international study of the relation between somatic symptoms and depression. N Engl J Med 1999; 341: 1329-1335. Go to original source... Go to PubMed...
    33. Švestka J. Antidepresiva a bolestivá porucha. Jsou analgeticky stejně účinná noradrenergní, serotonergní a smíšená (noradrenergní + serotonergní) antidepresiva? Bolest 1999; 2: 119-126.
    34. Švestka J. Duloxetin - duální specifický inhibitor reuptake serotoninu a noradrenalinu v léčbě akutní depresivní poruchy. Psychiatrie 2005; 9: 23-30.
    35. Vitton O, Gendreau M, Gendreau J. A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Hum Psychopharmacol 2004; 19 (suppl 1): S27-S35. Go to original source... Go to PubMed...

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.